[1] |
张媛, 林鹏, 李艳, 等. 美沙酮维持治疗者脱失风险评估量表的预测效度评价[J]. 中华疾病控制杂志, 2012, 16(12): 1040–1043.
Zhang Y, Lin P, Li Y, et al.
Validity evaluation on dropout risk assessment scale for methadone maintenance treatment patients[J]. Chin J Dis Control Prev, 2012, 16(12): 1040–1043.
|
|
[2] |
Cao XB, Wu ZY, Li L, et al.
Retention and its predictors among methadone maintenance treatment clients in China:a six-year cohort study[J]. Drug Alcohol Depend, 2014, 145: 87–93.
DOI:10.1016/j.drugalcdep.2014.09.776 |
|
[3] |
Chen X, He JM, Ding LS, et al.
Prevalence of hepatitis B virus and hepatitis C virus in patients with human immunodeficiency virus infection in Central China[J]. Arch Virol, 2013, 158(9): 1889–1894.
DOI:10.1007/s00705-013-1681-z |
|
[4] |
Akbarzadeh V, Mumtaz GR, Awad SF, et al.
HCV prevalence can predict HIV epidemic potential among people who inject drugs:mathematical modeling analysis[J]. BMC Public Health, 2016, 16(1): 1216.
DOI:10.1186/s12889-016-3887-y |
|
[5] |
Birger RB, Le T, Kouyos RD, et al.
The impact of HCV therapy in a high HIV-HCV prevalence population:a modeling study on people who inject drugs in Ho Chi Minh City, Vietnam[J]. PLoS One, 2017, 12(5): e0177195.
DOI:10.1371/journal.pone.0177195 |
|
[6] |
Zou X, Ling L, Zhang L.
Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China:a 7-year retrospective cohort study[J]. BMJ Open, 2015, 5(8): e008162.
DOI:10.1136/bmjopen-2015-008162 |
|
[7] |
Wang CH, Shi CX, Rou KM, et al.
Baseline HCV antibody prevalence and risk factors among drug users in China's national methadone maintenance treatment program[J]. PLoS One, 2016, 11(2): e0147922.
DOI:10.1371/journal.pone.0147922 |
|
[8] |
邱宏, 余德新, 王晓蓉, 等. logistic回归模型中交互作用的分析及评价[J]. 中华流行病学杂志, 2008, 29(9): 934–937.
Qiu H, Yu DX, Wang XR, et al.
Study on the interaction under logistic regression modeling[J]. Chin J Epidemiol, 2008, 29(9): 934–937.
DOI:10.3321/j.issn:0254-6450.2008.09.019 |
|
[9] |
Liao MZ, Kang DM, Tao XR, et al.
Syndemics of syphilis, HCV infection, and methamphetamine use along the east coast of China[J]. BMC Public Health, 2014, 14: 172.
DOI:10.1186/1471-2458-14-172 |
|
[10] |
王昊鹏, 杨静静, 邓小昭, 等. 中国大陆吸毒人群HIV、HBV、HCV感染状况及其相关因素的Meta分析[J]. 中华疾病控制杂志, 2010, 14(4): 300–304.
Wang HP, Yang JJ, Deng XZ, et al.
HIV/HBV/HCV infection among drug users:a Meta analysis of data collected in Chinese mainland[J]. Chin J Dis Control Prev, 2010, 14(4): 300–304.
|
|
[11] |
姚琦. 黄浦区美沙酮社区药物维持治疗依从性及影响因素研究[D]. 上海: 复旦大学, 2010.
Yao Q. Treatment compliance and its determinants in the community methadone maintenance clinic in Huangpu District[D]. Shanghai: Fudan University, 2010.
|
|
[12] |
李春霞, 王君, 潘明虎, 等. 美沙酮维持治疗人群高危性行为相关因素及交互作用分析[J]. 中华流行病学杂志, 2016, 37(6): 796–800.
Li CX, Wang J, Pan MH, et al.
Related factors and interaction on high-risk sexual behaviors among patients under the methadone maintenance treatment[J]. Chin J Epidemiol, 2016, 37(6): 796–800.
DOI:10.3760/cma.j.issn.0254-6450.2016.06.011 |
|
[13] |
Hosseini M, SeyedAlinaghi S, Kheirandish P, et al.
Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran[J]. Arch Iran Med, 2010, 13(4): 318–323.
|
|
[14] |
Solomon SS, Srikrishnan AK, Mehta SH, et al.
High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India:a cause for concern[J]. J Acquir Immune Defic Syndr, 2008, 49(3): 327–332.
DOI:10.1097/QAI.0b013e3181831e85 |
|
[15] |
韦莉, 张渝婧. 柳州市吸毒人群HIV、HCV和梅毒感染状况及影响因素分析[J]. 中华疾病控制杂志, 2015, 19(12): 1248–1251, 1264.
Wei L, Zhang YJ.
Prevalence and associated risk factors of HIV, HCV and TP in drug users in Liuzhou City[J]. Chin J Dis Control Prev, 2015, 19(12): 1248–1251, 1264.
DOI:10.16462/j.cnki.zhjbkz.2015.12.016 |
|
[16] |
Vazirian M, Nassirimanesh B, Zamani S, et al.
Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran:a cross-sectional study[J]. Harm Reduct J, 2005, 2: 19.
DOI:10.1186/1477-7517-2-19 |
|
[17] |
World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence[DB/OL]. Geneva: (WHO), 2009. (2009-01-01)[2017-08-20]. https://www.ncbi.nlm.nih.gov/books/NBK143185/.
|
|
[18] |
赵晶, 肖瑶. HIV/HCV共感染国内外研究进展[J]. 中国艾滋病性病, 2009, 15(1): 94–96.
Zhao J, Xiao Y.
HIV/HCV co-infection research progress at home and abroad[J]. Chin J AIDS STD, 2009, 15(1): 94–96.
|
|
[19] |
曹晓斌. 我国首批8个美沙酮维持治疗门诊2004年入组治疗者随访研究[D]. 济南: 中国疾病预防控制中心, 2011: 109.
Cao XB. Retention and its associated factors among clients of the eight pilot methadone maintenance treatment clinics in China: a prospective cohort study[D]. Jinan: Chinese Center for Disease Control and Prevention, 2011: 109.
|
|
[20] |
Zhang L, Chow EPF, Zhuang X, et al.
Methadone maintenance treatment participant retention and behavioural effectiveness in China:a systematic review and Meta-analysis[J]. PLoS One, 2013, 8(7): e68906.
DOI:10.1371/journal.pone.0068906 |
|
[21] |
Launonen E, Wallace I, Kotovirta E, et al.
Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients[J]. Drug Alcohol Depend, 2016, 162: 227–235.
DOI:10.1016/j.drugalcdep.2016.03.017 |
|
[22] |
何林. 美沙酮维持治疗门诊HIV阳性服药人员保持及其影响因素研究[D]. 合肥: 安徽医科大学, 2013: 79.
He L. Retention and its associated factors among HIV-seropositive drug users receiving methadone maintenance treatment[D]. Hefei: Anhui Medical University, 2013: 79.
|
|